May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Intravitreal Triamcinolone in Eyes with Cystoid Macular Edema Secondary to Branch Vein Occlusion
Author Affiliations & Notes
  • S. Bearelly
    Ophthalmology, Duke University, Durham, NC
  • S. Fekrat
    Ophthalmology, Duke University, Durham, NC
  • M.J. Cooney
    Ophthalmology, Duke University, Durham, NC
  • Footnotes
    Commercial Relationships  S. Bearelly, None; S. Fekrat, None; M.J. Cooney, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 5235. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. Bearelly, S. Fekrat, M.J. Cooney; Intravitreal Triamcinolone in Eyes with Cystoid Macular Edema Secondary to Branch Vein Occlusion . Invest. Ophthalmol. Vis. Sci. 2004;45(13):5235.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To evaluate the effectiveness of intravitreal triamcinolone in treating patients with cystoid macular edema (CME) related to branch retinal vein occlusion (BRVO). Methods: Retrospective chart review of 8 patients who underwent intravitreal triamcinolone injection for CME related to BRVO. Eyes were diagnosed clinically and confirmed with fluorescein angiography. When possible, an OCT (optical coherence tomogram) was obtained to quantitate the macular edema. Triamcinolone acetonide (4mg) was injected intravitreally using a sterile fashion. On follow–up, the parameters measured included visual acuity utilizing the ETDRS chart, as well as intraocular pressures. The volumetric OCT was obtained when available. All eyes were observed for complications. Results: All eyes were followed for an average of 4.38 months. Mean initial visual acuity was 20/230 with a mean change in visual acuity to 20/125. Although this had a trend toward clinical significance, it did not attain statistical significance (p=0.125, Wilcoxan signed rank test). Intraocular pressures were not significantly altered (p=0.875). Four out of the eight eyes (50%) improved. Four out of the eight eyes (50%) displayed a return to pre–injection visual acuity after a transient improvement. None of the eyes displayed a worsening of vision. One eye showed cataract progression. No complications such as endophthalmitis, retinal detachment, vitreous hemorrhage, or persistent elevation in intraocular pressure were observed. Conclusions: In this small review, intravitreal triamcinolone shows a trend towards clinical significance, however given the limited numbers of patients, this did not achieve statistical significance. Further study is needed to better define the role of intravitreal triamcinolone injection relative to standard focal grid laser per the Branch Vein Occlusion Study and newer treatments such as arteriovenous sheathotomy.

Keywords: vascular occlusion/vascular occlusive disease • corticosteroids • macula/fovea 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×